×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
JAZZ – jazz pharmaceuticals plc - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
JAZZ
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/15
07:00 am
jazz
Jazz Pharmaceuticals to Present Data at 2023 AACR Annual Meeting Showcasing New Zepzelca® (lurbinectedin) Data and Expanded Oncology Pre-Clinical and Clinical Pipeline
Low
Report
Jazz Pharmaceuticals to Present Data at 2023 AACR Annual Meeting Showcasing New Zepzelca® (lurbinectedin) Data and Expanded Oncology Pre-Clinical and Clinical Pipeline
3/15
07:00 am
jazz
Jazz Pharmaceuticals to Present Data at 2023 AACR Annual Meeting Showcasing New Zepzelca® (lurbinectedin) Data and Expanded Oncology Pre-Clinical and Clinical Pipeline
Low
Report
Jazz Pharmaceuticals to Present Data at 2023 AACR Annual Meeting Showcasing New Zepzelca® (lurbinectedin) Data and Expanded Oncology Pre-Clinical and Clinical Pipeline
3/13
04:23 am
jazz
Future of Asparaginase Market by 2029: Trends and Predictions [MarketWatch]
Low
Report
Future of Asparaginase Market by 2029: Trends and Predictions [MarketWatch]
3/8
12:03 am
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
3/6
08:11 am
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $204.00 price target on the stock.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $204.00 price target on the stock.
3/4
02:46 pm
jazz
Pharma Mar, S.A. (PHMMF) Q4 2022 Earnings Call Transcript [Seeking Alpha]
Low
Report
Pharma Mar, S.A. (PHMMF) Q4 2022 Earnings Call Transcript [Seeking Alpha]
3/3
01:08 pm
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $190.00 to $212.00. They now have a "buy" rating on the stock.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $190.00 to $212.00. They now have a "buy" rating on the stock.
3/2
08:28 am
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at Needham & Company LLC from $210.00 to $205.00. They now have a "buy" rating on the stock.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at Needham & Company LLC from $210.00 to $205.00. They now have a "buy" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
3/1/2023
04:05 pm
jazz
jazz pharmaceuticals plc - ordinary shares
MISS
Report
2.7%
jazz pharmaceuticals plc - ordinary shares
11/9/2022
04:05 pm
jazz
jazz pharmaceuticals plc - ordinary shares
BEAT
Report
7.1%
jazz pharmaceuticals plc - ordinary shares
8/3/2022
04:05 pm
jazz
jazz pharmaceuticals plc - ordinary shares
BEAT
Report
-1.5%
jazz pharmaceuticals plc - ordinary shares
5/4/2022
04:10 pm
jazz
jazz pharmaceuticals plc - ordinary shares
BEAT
Report
-2.7%
jazz pharmaceuticals plc - ordinary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/17
06:11 pm
jazz
Form 4 Jazz Pharmaceuticals For: Mar 15 Filed by: Carr Patricia
Low
Report
Form 4 Jazz Pharmaceuticals For: Mar 15 Filed by: Carr Patricia
3/10
06:11 pm
jazz
Form 4 Jazz Pharmaceuticals For: Mar 08 Filed by: Sablich Kim
Low
Report
Form 4 Jazz Pharmaceuticals For: Mar 08 Filed by: Sablich Kim
3/9
06:34 pm
jazz
Form 4 Jazz Pharmaceuticals For: Mar 07 Filed by: O'Keefe Kenneth W
Low
Report
Form 4 Jazz Pharmaceuticals For: Mar 07 Filed by: O'Keefe Kenneth W
3/7
09:34 pm
jazz
Form 4 Jazz Pharmaceuticals For: Mar 03 Filed by: Larkin Finbar
Low
Report
Form 4 Jazz Pharmaceuticals For: Mar 03 Filed by: Larkin Finbar
3/7
09:27 pm
jazz
Form 4 Jazz Pharmaceuticals For: Mar 03 Filed by: Swisher Daniel N JR
Low
Report
Form 4 Jazz Pharmaceuticals For: Mar 03 Filed by: Swisher Daniel N JR
3/7
09:23 pm
jazz
Form 4 Jazz Pharmaceuticals For: Mar 03 Filed by: Iannone Robert
Low
Report
Form 4 Jazz Pharmaceuticals For: Mar 03 Filed by: Iannone Robert
3/7
09:19 pm
jazz
Form 4 Jazz Pharmaceuticals For: Mar 03 Filed by: Carr Patricia
Low
Report
Form 4 Jazz Pharmaceuticals For: Mar 03 Filed by: Carr Patricia
3/7
09:15 pm
jazz
Form 4 Jazz Pharmaceuticals For: Mar 03 Filed by: GALA RENEE D
Low
Report
Form 4 Jazz Pharmaceuticals For: Mar 03 Filed by: GALA RENEE D
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/7
Q1/2019 3/31/2019 EPS 3.670 ZacksConsensus 2.830 ActVsEst 0.840 - Beat
9.3%
4/6 Jefferies sees 51% upside in Jazz Pharma in premarket analyst action [Seeking Alpha] 7.1%
9/10 Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. 5.0%
11/14 Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences 3.7%
11/7 Form 3 Jazz Pharmaceuticals For: Oct 31 Filed by: Larkin Finbar 3.3%
1/14 Form 8-K Jazz Pharmaceuticals For: Jan 13 3.0%
4/24 Form 10-K/A Jazz Pharmaceuticals For: Dec 31 2.8%
12/19 PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement for Lurbinectedin in the U.S. 2.6%
11/22 Edited Transcript of JAZZ earnings conference call or presentation 5-Nov-19 9:30pm GMT [Yahoo! Finance News] 2.6%
4/28 Can This Small-Cap Biotech Win a $1 Billion Market Opportunity for Narcolepsy? [The Motley Fool] 2.5%
4/6 Jefferies sees 51% upside in Jazz Pharma in premarket analyst action [Seeking Alpha] 7.1%
9/10 Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. 5.0%
11/14 Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences 3.7%
11/7 Form 3 Jazz Pharmaceuticals For: Oct 31 Filed by: Larkin Finbar 3.3%
1/14 Form 8-K Jazz Pharmaceuticals For: Jan 13 3.0%
4/24 Form 10-K/A Jazz Pharmaceuticals For: Dec 31 2.8%
12/19 PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement for Lurbinectedin in the U.S. 2.6%
11/22 Edited Transcript of JAZZ earnings conference call or presentation 5-Nov-19 9:30pm GMT [Yahoo! Finance News] 2.6%
4/28 Can This Small-Cap Biotech Win a $1 Billion Market Opportunity for Narcolepsy? [The Motley Fool] 2.5%
TOP News Decliners
3/13
Form 4 Jazz Pharmaceuticals For: Mar 12 Filed by: MILLER MICHAEL PATRICK
-11.3%
2/25 Q4/2019 12/31/2019 EPS 4.420 ZacksConsensus 3.610 ActVsEst 0.810 - Beat -8.4%
3/3 Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -7.8%
6/17 Jazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi™ (solriamfetol) -7.1%
10/7 Form 8-K Jazz Pharmaceuticals For: Oct 03 -5.6%
8/6 Jazz Pharmaceuticals Announces Second Quarter 2019 Financial Results -4.8%
11/5 Jazz Pharmaceuticals EPS beats by $0.51, beats on revenue [Seeking Alpha] -4.3%
3/31 Jazz Pharmaceuticals Provides COVID-19 Business Update -4.1%
3/5 Form 4 Jazz Pharmaceuticals For: Mar 03 Filed by: Carr Patricia -3.8%
4/29 Jazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease -3.6%
2/25 Q4/2019 12/31/2019 EPS 4.420 ZacksConsensus 3.610 ActVsEst 0.810 - Beat -8.4%
3/3 Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -7.8%
6/17 Jazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi™ (solriamfetol) -7.1%
10/7 Form 8-K Jazz Pharmaceuticals For: Oct 03 -5.6%
8/6 Jazz Pharmaceuticals Announces Second Quarter 2019 Financial Results -4.8%
11/5 Jazz Pharmaceuticals EPS beats by $0.51, beats on revenue [Seeking Alpha] -4.3%
3/31 Jazz Pharmaceuticals Provides COVID-19 Business Update -4.1%
3/5 Form 4 Jazz Pharmaceuticals For: Mar 03 Filed by: Carr Patricia -3.8%
4/29 Jazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease -3.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: